Cargando…

Trends in Brazilian market of antidepressants: A five-year dataset analysis

Introduction: Depression is an emotional disorder associated with morbidities and disabilities worldwide. The growing use of antidepressants is a concern for health managers because there are still unanswered questions on the effectiveness and safety of these medicines. Drug sales have increased in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoefler, Rogério, Galvão, Taís Freire, Ribeiro-Vaz, Inês, Silva, Marcus Tolentino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577407/
https://www.ncbi.nlm.nih.gov/pubmed/36267285
http://dx.doi.org/10.3389/fphar.2022.893891
_version_ 1784811750020874240
author Hoefler, Rogério
Galvão, Taís Freire
Ribeiro-Vaz, Inês
Silva, Marcus Tolentino
author_facet Hoefler, Rogério
Galvão, Taís Freire
Ribeiro-Vaz, Inês
Silva, Marcus Tolentino
author_sort Hoefler, Rogério
collection PubMed
description Introduction: Depression is an emotional disorder associated with morbidities and disabilities worldwide. The growing use of antidepressants is a concern for health managers because there are still unanswered questions on the effectiveness and safety of these medicines. Drug sales have increased in Brazil in recent years, but investigations on antidepressants sales are not available. We aimed to describe the trends in the antidepressant commerce in Brazil in a five-year period. Materials and Methods: We performed an ecological study on antidepressant sales in Brazil, from November 2014 to October 2019, using data from IQVIA™, a data provider of pharmaceutical sales. Antidepressants were coded by the Anatomical Therapeutic Chemical classification system, and sales were presented in defined daily doses (DDDs) and DDDs per 1,000 inhabitants per day (DIDs). The results were expressed in absolute quantities and growth rates. Results: The analyzed dataset contained 23 active substances in 780 products. The total sales of antidepressants increased from 23.3 DIDs in November 2014 to 38.3 DIDs in October 2019 (p = 0.002). Selective serotonin reuptake inhibitors were the most sold category of drugs (+5.7 million DDDs) in the period. ‘Other’ antidepressants presented the largest growth rate (104.7%). Individually, the most sold active substance was escitalopram (+1.8 million DDDs), and vortioxetine had the largest growth rate (336.2%). Tricyclic sales remained unchanged, and monoamine oxidase inhibitors had low and even decreasing sales (−9.5%). Discussion: The total sales of antidepressants increased in Brazil from November 2014 to October 2019. The higher sale volumes of selective serotonin reuptake inhibitors and higher growth rate of ‘other’ antidepressants, with low sale volume of tricyclics and a decrease of monoamine oxidase inhibitors, suggest the replacement of older drugs by newer ones following a global trend. Therapeutic advances and commercial promotion efforts on new products might explain these findings.
format Online
Article
Text
id pubmed-9577407
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95774072022-10-19 Trends in Brazilian market of antidepressants: A five-year dataset analysis Hoefler, Rogério Galvão, Taís Freire Ribeiro-Vaz, Inês Silva, Marcus Tolentino Front Pharmacol Pharmacology Introduction: Depression is an emotional disorder associated with morbidities and disabilities worldwide. The growing use of antidepressants is a concern for health managers because there are still unanswered questions on the effectiveness and safety of these medicines. Drug sales have increased in Brazil in recent years, but investigations on antidepressants sales are not available. We aimed to describe the trends in the antidepressant commerce in Brazil in a five-year period. Materials and Methods: We performed an ecological study on antidepressant sales in Brazil, from November 2014 to October 2019, using data from IQVIA™, a data provider of pharmaceutical sales. Antidepressants were coded by the Anatomical Therapeutic Chemical classification system, and sales were presented in defined daily doses (DDDs) and DDDs per 1,000 inhabitants per day (DIDs). The results were expressed in absolute quantities and growth rates. Results: The analyzed dataset contained 23 active substances in 780 products. The total sales of antidepressants increased from 23.3 DIDs in November 2014 to 38.3 DIDs in October 2019 (p = 0.002). Selective serotonin reuptake inhibitors were the most sold category of drugs (+5.7 million DDDs) in the period. ‘Other’ antidepressants presented the largest growth rate (104.7%). Individually, the most sold active substance was escitalopram (+1.8 million DDDs), and vortioxetine had the largest growth rate (336.2%). Tricyclic sales remained unchanged, and monoamine oxidase inhibitors had low and even decreasing sales (−9.5%). Discussion: The total sales of antidepressants increased in Brazil from November 2014 to October 2019. The higher sale volumes of selective serotonin reuptake inhibitors and higher growth rate of ‘other’ antidepressants, with low sale volume of tricyclics and a decrease of monoamine oxidase inhibitors, suggest the replacement of older drugs by newer ones following a global trend. Therapeutic advances and commercial promotion efforts on new products might explain these findings. Frontiers Media S.A. 2022-10-04 /pmc/articles/PMC9577407/ /pubmed/36267285 http://dx.doi.org/10.3389/fphar.2022.893891 Text en Copyright © 2022 Hoefler, Galvão, Ribeiro-Vaz and Silva. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Hoefler, Rogério
Galvão, Taís Freire
Ribeiro-Vaz, Inês
Silva, Marcus Tolentino
Trends in Brazilian market of antidepressants: A five-year dataset analysis
title Trends in Brazilian market of antidepressants: A five-year dataset analysis
title_full Trends in Brazilian market of antidepressants: A five-year dataset analysis
title_fullStr Trends in Brazilian market of antidepressants: A five-year dataset analysis
title_full_unstemmed Trends in Brazilian market of antidepressants: A five-year dataset analysis
title_short Trends in Brazilian market of antidepressants: A five-year dataset analysis
title_sort trends in brazilian market of antidepressants: a five-year dataset analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577407/
https://www.ncbi.nlm.nih.gov/pubmed/36267285
http://dx.doi.org/10.3389/fphar.2022.893891
work_keys_str_mv AT hoeflerrogerio trendsinbrazilianmarketofantidepressantsafiveyeardatasetanalysis
AT galvaotaisfreire trendsinbrazilianmarketofantidepressantsafiveyeardatasetanalysis
AT ribeirovazines trendsinbrazilianmarketofantidepressantsafiveyeardatasetanalysis
AT silvamarcustolentino trendsinbrazilianmarketofantidepressantsafiveyeardatasetanalysis